REDUCE MRSA Study Earns "Distinguished Clinical Research Achievement Award"

REDUCE MRSA, a comprehensive infection prevention study conducted exclusively at 43 HCA-affiliated hospitals, has earned a "Distinguished Clinical Research Achievement Award" from The Clinical Research Forum. The award recognizes outstanding accomplishments in clinical research.

The research project was cited as being among, "the best and most compelling examples of scientific innovation resulting from the nation's investment in research that benefits human health."

REDUCE MRSA involved nearly 75,000 patients and more than 280,000 patient days, in 74 adult Intensive Care Units (ICUs), located in 16 states. It was conducted in conjunction with investigators at Harvard and several other academic institutions, and research programs at two U.S. Department of Health and Human Services agencies, the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Disease Control and Prevention (CDC).

REDUCE MRSA found that all bloodstream infections were decreased by more than 40% by using germ-killing soap and ointment. In particular, the presence of methicillin-resistant Staphylococcus (MRSA) was greatly reduced in patients. The findings indicate a major change in healthcare practice that could save lives. For every 54 patients who were decolonized by using the soap and ointment, one bloodstream infection was prevented.

This study exemplifies the ideals of a learning health system, defined by the Institute of Medicine as "institutions that both generate and use evidence to guide clinical decision-making.

REDUCE MRSA Information

Distinguished Clinical Research Achievement Awards